Patents by Inventor Stephen Wright

Stephen Wright has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190078028
    Abstract: Systems and methods for separation of hydrocarbon containing fluids are provided. More particularly, the disclosure is relevant to separating fluids having a gas phase, a hydrocarbon liquid phase, and an aqueous liquid phase using indirect heating. In general, the system uses a first gas separation followed by pressure reduction and then a second gas separation. Indirect follows the second gas separation and then three-phase separation.
    Type: Application
    Filed: September 7, 2018
    Publication date: March 14, 2019
    Applicant: John Zink Company, LLC
    Inventors: Stephen Rehm, Timothy Oneal, Gene Bittel, Mark Ferguson, Daniel Wright, Nicholas Jensen, Todd Earls
  • Publication number: 20190071448
    Abstract: A compound compound having the structure: or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of said compound or pharmaceutically acceptable salt, wherein A, A? and A? are independently O, C?O, C—R? or N—R?, where R? and R? may independently be H, amino, —NR7COR6, COR6, —CONR7R8, C1-C6 alkyl, or hydroxy(C1-C6 alkyl), and R? may be present or absent, and is present where the rules of valency permit, and where not more than one of A, A? and A? is O or C?O; R0 and R are independently H, Br, Cl, F, or C1-C6 alkyl; R1 is H, C1-C6 alkyl, or hydroxy(C1-C6 alkyl); R2 is selected from the group consisting of H, C1-C6 alkyl, C1-C6 alkoxy, hydroxy(C1-C6 alkyl), phenyl(C1-C6 alkyl), formyl, heteroaryl, heterocyclic, —COR6, —OCOR6, —COOR6, —NR7COR6, —CONR7R8, and —(CH2)n—W, where W is cyano, hydroxy, C3-C8 cycloalkyl, —SO2NR7R8, and —SO2—R9, where R9 is C1-C6 alkyl, C3-C8 cycloalkyl, heteroaryl, or heterocyclic; wherein each of said alkyl, cycloalkyl, heterocyclic, or heteroaryl ma
    Type: Application
    Filed: November 6, 2018
    Publication date: March 7, 2019
    Applicant: Pfizer Inc.
    Inventors: Matthew Frank BROWN, Alpay DERMENCI, Andrew FENSOME, Brian Stephen GERSTENBERGER, Matthew Merrill HAYWARD, Dafydd Rhys OWEN, Stephen Wayne WRIGHT, Li Huang XING, Xiaojing YANG
  • Publication number: 20190070128
    Abstract: The present invention relates to the use of cannabidivarin (CBDV) in the treatment of autism spectrum disorder (ASD) and ASD-associated disorders such as Fragile X syndrome (FXS); Rett syndrome (RS); or Angelman syndrome (AS). In a further embodiment the invention relates to the use of CBDV in the treatment of schizophrenia. CBDV has been shown to be particularly effective in improving cognitive dysfunction in rodent models of ASD, FXS, RS, AS and schizophrenia. The CBDV is preferably substantially pure. It may take the form of a highly purified extract of cannabis such that the CBDV is present at greater than 95% of the total extract (w/w) and the other components of the extract are characterised. Alternatively, the CBDV is synthetically produced.
    Type: Application
    Filed: September 7, 2018
    Publication date: March 7, 2019
    Inventors: Geoffrey GUY, Stephen WRIGHT, James BRODIE, Marie WOOLLEY-ROBERTS, Rafael MALDONADO, Daniela PAROLARO, Livio LUONGO, Joanna NEILL
  • Publication number: 20190040185
    Abstract: A method of forming a polymer comprising repeat units of formula (II) or a salt thereof by forming a precursor polymer of formula (I) and converting the precursor polymer to the polymer comprising repeat units of formula (II): (Formulae (II), (III)) wherein BG is a backbone group; Sp1 and Sp2 are each a spacer group; x is 0 or 1; y is at least 1; X is O or NR2 wherein R2 is H or a substituent; P is selected from the group consisting of unsubstituted or substituted benzyl, CR13, COR1, COOR1 or, if X?O, SiR13; wherein R1 in each occurrence is a C1-20 hydrocarbyl group; R3 in each occurrence is a substituent; and z is 0 or a positive integer. The polymer of formula (II) may form a layer of an organic electronic device and the layer may be formed by deposition of the polymer dissolved in a polar solvent.
    Type: Application
    Filed: February 16, 2017
    Publication date: February 7, 2019
    Applicants: Cambridge Display Technology Limited, Sumitomo Chemical Company Limited
    Inventors: Florence Bourcet, Stephen Wright, Jean-Benoit Giguere
  • Publication number: 20180344660
    Abstract: This invention relates to the use of CBD to treat mental disorders.
    Type: Application
    Filed: September 8, 2016
    Publication date: December 6, 2018
    Applicant: GW Pharma Limited
    Inventors: Philip Robson, Geoffrey Guy, Stephen Wright, Emma Cheetham, Dominic Schiller
  • Publication number: 20180338931
    Abstract: The present disclosure relates to the use of cannabidiol (CBD) for the reduction of total convulsive seizure frequency in the treatment of “treatment-resistant epilepsy” (TRE). In particular, the disclosure relates to the use of CBD of treating TRE when the TRE is Dravet syndrome; myoclonic absence seizures or febrile infection related epilepsy syndrome (FIRES). The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).
    Type: Application
    Filed: April 9, 2018
    Publication date: November 29, 2018
    Inventors: Geoffrey Guy, Stephen Wright, Alice Mead, Orrin Devinsky
  • Patent number: 10137474
    Abstract: A method and apparatus for depositing a fluid over an interface. A nozzle may comprise a body having a first end and a second end, an input located at the first end of the body, an output located at the second end of the body, and a plurality of channels located within the body. The input may be configured to receive a fluid. The plurality of channels may have a configuration that causes the fluid received through the input to flow through the plurality of channels and exit the output to form a deposition having a desired shape over an interface.
    Type: Grant
    Filed: April 27, 2017
    Date of Patent: November 27, 2018
    Assignee: The Boeing Company
    Inventors: Chin H. Toh, Trent Rob Logan, John Walter Pringle, IV, Rodney Stephen Wright
  • Patent number: 10137095
    Abstract: The present disclosure relates to the use of cannabidiol (CBD) for the treatment of atonic seizures. In particular the CBD appears particularly effective in reducing atonic seizures in patients suffering with etiologies that include: Lennox-Gastaut Syndrome; Tuberous Sclerosis Complex; Dravet Syndrome; Doose Syndrome; Aicardi syndrome; CDKL5 and Dup15q in comparison to other seizure types. The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).
    Type: Grant
    Filed: March 3, 2017
    Date of Patent: November 27, 2018
    Assignee: GW Pharma Limited
    Inventors: Geoffrey Guy, Stephen Wright, Alice Mead, Orrin Devinsky
  • Patent number: 10111840
    Abstract: The present disclosure relates to the use of cannabidiol (CBD) for the treatment of atonic seizures. In particular the CBD appears particularly effective in reducing atonic seizures in patients suffering with etiologies that include: Lennox-Gastaut Syndrome; Tuberous Sclerosis Complex; Dravet Syndrome; Doose Syndrome; Aicardi syndrome; CDKL5 and Dup15q in comparison to other seizure types. The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).
    Type: Grant
    Filed: October 13, 2015
    Date of Patent: October 30, 2018
    Assignee: GW Pharma Limited
    Inventors: Geoffrey Guy, Stephen Wright, Alice Mead, Orrin Devinsky
  • Patent number: 10092525
    Abstract: The present disclosure relates to the use of cannabidiol (CBD) for the treatment of atonic seizures. In particular the CBD appears particularly effective in reducing atonic seizures in patients suffering with etiologies that include: Lennox-Gastaut Syndrome; Tuberous Sclerosis Complex; Dravet Syndrome; Doose Syndrome; Aicardi syndrome; CDKL5 and Dup15q in comparison to other seizure types. The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).
    Type: Grant
    Filed: March 3, 2017
    Date of Patent: October 9, 2018
    Assignee: GW Pharma Limited
    Inventors: Geoffrey Guy, Stephen Wright, Alice Mead, Orrin Devinsky
  • Publication number: 20180259379
    Abstract: There is disclosed inhaler testing apparatus, in which at least one flow regulation valve, such as a needle valve, is located within a conduit. The flow regulation valve divides the conduit into inlet and outlet sides of the valve. The inlet side is arranged for connection to an inhaler and the outlet side for connection to a vacuum source. An electric motor provides variable adjustment of a flow opening through the valve. At least one sensor senses pressure or flow rate in the inlet side and a controller automatically adjusts the flow opening through the valve in response to readings from the at least one sensor. The apparatus may also comprise a shut off valve, such as a solenoid valve.
    Type: Application
    Filed: January 19, 2018
    Publication date: September 13, 2018
    Inventors: Mark Andrew COPLEY, Benjamin BRADLEY, Ian Christopher EVANS, Jonathan Charles Stephen WRIGHT
  • Patent number: 9956185
    Abstract: The present disclosure relates to the use of cannabidiol (CBD) for the reduction of total convulsive seizure frequency in the treatment of “treatment-resistant epilepsy” (TRE). In particular, the disclosure relates to the use of CBD of treating TRE when the TRE is Dravet syndrome; myoclonic absence seizures or febrile infection related epilepsy syndrome (FIRES). The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).
    Type: Grant
    Filed: March 3, 2017
    Date of Patent: May 1, 2018
    Assignee: GW Pharma Limited
    Inventors: Geoffrey Guy, Stephen Wright, Alice Mead, Orrin Devinsky
  • Patent number: 9956186
    Abstract: The present disclosure relates to the use of cannabidiol (CBD) for the reduction of total convulsive seizure frequency in the treatment of “treatment-resistant epilepsy” (TRE). In particular, the disclosure relates to the use of CBD of treating TRE when the TRE is Dravet syndrome; myoclonic absence seizures or febrile infection related epilepsy syndrome (FIRES). The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).
    Type: Grant
    Filed: March 3, 2017
    Date of Patent: May 1, 2018
    Assignee: GW Pharma Limited
    Inventors: Geoffrey Guy, Stephen Wright, Alice Mead, Orrin Devinsky
  • Patent number: 9956183
    Abstract: The present disclosure relates to the use of cannabidiol (CBD) for the reduction of total convulsive seizure frequency in the treatment of “treatment-resistant epilepsy” (TRE). In particular, the disclosure relates to the use of CBD of treating TRE when the TRE is Dravet syndrome; myoclonic absence seizures or febrile infection related epilepsy syndrome (FIRES). The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).
    Type: Grant
    Filed: March 3, 2017
    Date of Patent: May 1, 2018
    Assignee: GW Pharma Limited
    Inventors: Geoffrey Guy, Stephen Wright, Alice Mead, Orrin Devinsky
  • Patent number: 9956184
    Abstract: The present disclosure relates to the use of cannabidiol (CBD) for the reduction of total convulsive seizure frequency in the treatment of “treatment-resistant epilepsy” (TRE). In particular, the disclosure relates to the use of CBD of treating TRE when the TRE is Dravet syndrome; myoclonic absence seizures or febrile infection related epilepsy syndrome (FIRES). The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).
    Type: Grant
    Filed: March 3, 2017
    Date of Patent: May 1, 2018
    Assignee: GW Pharma Limited
    Inventors: Geoffrey Guy, Stephen Wright, Alice Mead, Orrin Devinsky
  • Patent number: 9949936
    Abstract: The present disclosure relates to the use of cannabidiol (CBD) for the reduction of total convulsive seizure frequency in the treatment of “treatment-resistant epilepsy” (TRE). In particular, the disclosure relates to the use of CBD of treating TRE when the TRE is Dravet syndrome; myoclonic absence seizures or febrile infection related epilepsy syndrome (FIRES). The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).
    Type: Grant
    Filed: October 4, 2016
    Date of Patent: April 24, 2018
    Assignee: GW Pharma Limited
    Inventors: Geoffrey Guy, Stephen Wright, Alice Mead, Charuta Joshi, Angus Wilfong
  • Patent number: 9949937
    Abstract: The present disclosure relates to the use of cannabidiol (CBD) for the reduction of total convulsive seizure frequency in the treatment of “treatment-resistant epilepsy” (TRE). In particular, the disclosure relates to the use of CBD of treating TRE when the TRE is Dravet syndrome; myoclonic absence seizures or febrile infection related epilepsy syndrome (FIRES). The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).
    Type: Grant
    Filed: March 3, 2017
    Date of Patent: April 24, 2018
    Assignee: GW Pharma Limited
    Inventors: Geoffrey Guy, Stephen Wright, Alice Mead, Orrin Devinsky
  • Publication number: 20180042975
    Abstract: This invention relates to the use of phytocannabinoids, either in an isolated form or in the form of a botanical drug substance (BDS) in the treatment of cancer. Preferably the cancer to be treated is cancer of the prostate, cancer of the breast or cancer of the colon.
    Type: Application
    Filed: June 12, 2017
    Publication date: February 15, 2018
    Applicants: GW Pharma Limited, Otsuka Pharmaceutical Co., Limited
    Inventors: Daniela Parolaro, Paola Massi, Angelo Antonio Izzo, Francesca Borrelli, Gabriella Aviello, Vincenzo Di Marzo, Luciano De Petrocellis, Aniello Schiano Moriello, Alessia Ligresti, Ruth Alexandra Ross, Lesley Ann Ford, Sharon Anavi-Goffer, Manuel Guzman, Guillermo Velasco, Mar Lorente, Sofia Torres, Tetsuro Kikuchi, Geoffrey Guy, Colin Stott, Stephen Wright, Alan Sutton, David Potter, Etienne De Meijer
  • Patent number: 9862020
    Abstract: Method and apparatus for assembling, with fasteners, components of a structure having an outboard side, an inboard side, and a supporting frame. The components are placed together on the frame. An electromagnet having a core with multiple openings is positioned on the outboard side. A magnetically attractive member is placed against the inboard side opposite and aligned with the electromagnet. When activated, the electromagnet is attracted towards the magnetically attractive member and the two hold the components together. Multiple drill members pass through the openings in the core of the electromagnet and multiple openings are drilled simultaneously through the components. Subsequently, multiple rivets or huck bolts are simultaneously inserted into the drilled openings.
    Type: Grant
    Filed: September 16, 2015
    Date of Patent: January 9, 2018
    Assignee: The Boeing Company
    Inventors: Rodney Stephen Wright, David Hassan Amirehteshami, John W. Pringle, IV
  • Patent number: 9794375
    Abstract: A method, apparatus and non-transitory computer medium are provided for obtaining a required frame size for a first compressed data frame to be generated by compressing at least a first data frame of a media file, the first compressed data frame for use by a user equipment in a communications network. The method comprises, responsive to receiving a request for the media file from the user equipment, retrieving at least metadata of the media file. The required frame size for the first compressed data frame is determined based on a size of the at least a first data frame as indicated by the metadata, a compression parameter indicative of a requested compression factor for the at least a first data frame and a biasing factor that acts to reduce the effect of the requested compression factor.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: October 17, 2017
    Assignee: Openwave Mobility, Inc.
    Inventors: Declan Harrison, Stephen Wright, John Barr Rowe, Christopher Brown